Supplementary Data 1 from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration

Qing Wei,Teng Yang,Jiayu Zhu,Ziwen Zhang,Le Yang,Yuchao Zhang,Can Hu,Jiahui Chen,Jinchao Wang,Xuefei Tian,Takaya Shimura,Jianmin Fang,Jieer Ying,Mengyang Fan,Peng Guo,Xiangdong Cheng

DOI: https://doi.org/10.1158/1078-0432.25324490

2024-01-01

Abstract:Supplementary methods and figures

What problem does this paper attempt to address?

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Data from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration

Qing Wei,Teng Yang,Jiayu Zhu,Ziwen Zhang,Le Yang,Yuchao Zhang,Can Hu,Jiahui Chen,Jinchao Wang,Xuefei Tian,Takaya Shimura,Jianmin Fang,Jieer Ying,Mengyang Fan,Peng Guo,Xiangdong Cheng

DOI: https://doi.org/10.1158/1078-0432.ccr-23-1725

IF: 13.801

2024-01-01

Clinical Cancer Research

Abstract:AbstractPurpose: Antibody–drug conjugate (ADC) has had a transformative effect on the treatment of many solid tumors, yet it remains unclear how ADCs exert bystander activity in the tumor microenvironment. Experimental Design: Here, we directly visualized and spatiotemporally quantified the intratumor biodistribution and pharmacokinetics of different ADC components by developing dual-labeled fluorescent probes. Results: Mechanistically, we found that tumor penetration of ADCs is distinctly affected by their ability to breach the binding site barrier (BSB) in perivascular regions of tumor vasculature, and bystander activity of ADC can only partially breach BSB. Furthermore, bystander activity of ADCs can work in synergy with coadministration of their parental antibodies, leading to fully bypassing BSBs and enhancing tumor penetration via a two-step process. Conclusions: These promising preclinical data allowed us to initiate a phase I/II clinical study of coadministration of RC48 and trastuzumab in patients with malignant stomach cancer to further evaluate this treatment strategy in humans.
Supplementary Figure 8 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shuhui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089539

2023-01-01

Abstract:In vitro efficacy and bystander effect of AMT-562.
Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin,Liang Liu,Yun Xing,Tao Meng,Li Ma,Jinpeng Pei,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu

DOI: https://doi.org/10.1158/1535-7163.22519333

2023-01-01

Abstract:Supplementary Figures and Tables
Supplementary Methods from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394712

2023-01-01

Abstract:PDF file - 179K, Includes HEPA analysis data, Calculation of DP score, and supplementary references
Supplementary Methods, Figures 1-4 from Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

Guanglei Zhuang,Dana M. Brantley-Sieders,David Vaught,Jian Yu,Lu Xie,Sam Wells,Dowdy Jackson,Rebecca Muraoka-Cook,Carlos Arteaga,Jin Chen

DOI: https://doi.org/10.1158/0008-5472.22383389.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-4 from Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect

Xuejun Wen,Changrong Shi,Xinying Zeng,Liang Zhao,Lanlin Yao,Zhida Liu,Lixia Feng,Deliang Zhang,Jinxiong Huang,Yesen Li,Qin Lin,Haojun Chen,Rongqiang Zhuang,Xiaoyuan Chen,Xianzhong Zhang,Zhide Guo

DOI: https://doi.org/10.1158/1078-0432.22486374

2023-01-01

Abstract:Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Wen‐Jia Zuo,Yi‐Zhou Jiang,Yujie Wang,Xiao‐En Xu,Xin Hu,Guangyu Li,Jiong Wu,Gen-Hong Di,Ke‐Da Yu,Zhi‐Ming Shao

DOI: https://doi.org/10.1158/1078-0432.22467669

2023-01-01

Abstract:Supplementary Figure S1. Flowchart of study design. Supplementary Figure S2. Protein structure visualizations of the HER2 somatic mutations. Supplementary Figure S3. HER2 mutations L768S and V773L induce HER2 internalization. Supplementary Figure S4. Kaplan-Meier estimates of relapse-free survival (RFS) according to HER2 mutation in different regions.
Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

John O. DaSilva,Katie Yang,Andrés E. Perez Bay,Julian Andreev,Peter Ngoi,Erica Pyles,Matthew C. Franklin,Drew Dudgeon,Ashique Rafique,Anthony J. Dore,Frank J. Delfino,Terra Potocky,Robert G. Babb,Gang Chen,Douglas MacDonald,William C. Olson,Gavin Thurston,Christopher Daly

DOI: https://doi.org/10.1158/1078-0432.22479116

2023-01-01

Abstract:Supplementary figure legends and methods
Supplementary Figure 12 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shu-Hui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089572.v1

2023-01-01

Abstract:AMT-562 is more effective as single agent or in combination therapy for colorectal cancer.
Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Cuicui Liu,Jiankun Qiang,Qiaodan Deng,Jie Xia,Lu Deng,Lei Zhou,Dong Wang,Xueyan He,Ying Liu,Botao Zhao,Jinhui Lv,Zuoren Yu,Qun-Ying Lei,Zhi-Ming Shao,Xiao-Yong Zhang,Lixing Zhang,Suling Liu

DOI: https://doi.org/10.1158/0008-5472.22429821.v1

2023-01-01

Abstract:Supplementary Methods, Figures and Figure legends
Supplementary Fig.S12 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Wei Zhou,Fang Zheng Peng,Dongan Yu,Hongyuan Ren,Meng You,Long Yin,Fei Mei,Haitao Zhu,Zhenzhen Wang,Honglin Xu,Yuxia Cao,Xiaowei Sun,Xiaohong Xu,Jianjun Bi,Jin Wang,Lanping Ma,Xin Wang,Lin Chen,Yongliang Zhang,Xiaowei Cen,Xi Zhu,Liguang Lou,Datao Liu,Xiaoding Tan,Jinliang Yang,Tao Meng,Jingkang Shen

DOI: https://doi.org/10.1158/1535-7163.23814401

2023-01-01

Abstract:Mouse body weight from BL3578, CV13641, LU3073, BR9457, BR9479, BR1282 and BR1458 patient-derived xenograft studies.
Supplementary Methods, Figures S1-14 from Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

James R. Whittle,François Vaillant,Elliot Surgenor,Antonia N. Policheni,Göknur Giner,Bianca D. Capaldo,Huei‐Rong Chen,He K. Liu,Johanna F. Dekkers,Norman Sachs,Hans Clevers,Andrew Fellowes,Thomas Green,Huiling Xu,Stephen B. Fox,Marco J. Herold,Gordon K. Smyth,Daniel H.D. Gray,Jane E. Visvader,Geoffrey J. Lindeman

DOI: https://doi.org/10.1158/1078-0432.22475475

2023-01-01

Abstract:Supplemental Methods and Figures
Supplementary Figure 4 from Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Yu Cao,James D. Marks,Qian Huang,Stephen I. Rudnick,Chiyi Xiong,Walter N. Hittelman,Xiaoxia Wen,John W. Marks,Lawrence H. Cheung,Kim Boland,Chun Li,Gregory P. Adams,Michael G. Rosenblum

DOI: https://doi.org/10.1158/1535-7163.22498738.v1

2023-01-01

Abstract:PDF file - 2744KB, Ex vivo optical imaging of tumor and other organs after 24 and 72h postinjection of IRDye800-MH3-B1/rGel or IRDye800-B1D3/rGel using the Xenogen IVIS imaging system.
Supplementary Data from A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors

Xinyuan Lei,Zhanpeng Ou,Zhaohui Yang,Jianglong Zhong,Yanliang Zhu,Jing Tian,Jiannan Wu,Heran Deng,Xinyu Lin,Yu Peng,Bowen Li,Lile He,Zhiming Tu,Weixiong Chen,Qunxing Li,Niu Liu,Hanqing Zhang,Zhangsong Wang,Zezhen Fang,Teppei Yamada,Xiaobin Lv,Tian,Guokai Pan,Fan Wu,Liping Xiao,Lizao Zhang,Tingting Cai,Xinhui Wang,Bakhos A. Tannous,Jinsong Li,Filippos Kontos,Soldano Ferrone,Song Fan

DOI: https://doi.org/10.1158/1078-0432.22481297.v1

2023-01-01

Abstract:Supplementary methods, tables and figures
Supplementary Figure 5 from Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Yu Cao,James D. Marks,Qian Huang,Stephen I. Rudnick,Chiyi Xiong,Walter N. Hittelman,Xiaoxia Wen,John W. Marks,Lawrence H. Cheung,Kim Boland,Chun Li,Gregory P. Adams,Michael G. Rosenblum

DOI: https://doi.org/10.1158/1535-7163.22498735.v1

2023-01-01

Abstract:PDF file - 1877KB, Statistical comparisons of Tissue-to-Muscle Ratio (tumor or liver to muscle ratio) of IRDye800-MH3-B1/rGel and IRDye800-B1D3/rGel after 24h (A) and 72h (B) injection to BT474 M1 xenograft tumors.
Supplementary Figure 3 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng,Tao Meng,Junyi Pu,Linjie Ma,Yi Shen,Zhaohui Wang,Rong Pan,Mingqiao Wang,Caiwei Chen,Lijun Wang,Jianjian Zhang,Biao Zhou,Siyuan Shao,Yu Qian,Shuhui Liu,Wenhao Hu,Xun Meng

DOI: https://doi.org/10.1158/1535-7163.24089557

2023-01-01

Abstract:Stability and toxicity in monkey of HER2-targeting ADCs based on T800 and T1000.
Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study

Jian Zhang,Dongmei Ji,Li Cai,Herui Yao,Min Yan,Xiaojia Wang,Weina Shen,Yiqun Du,Hui Pang,Xiuping Lai,Huiai Zeng,Jian Huang,Yan Sun,Xinxin Peng,Junfang Xu,Jing Yang,Fei Yang,Ting Xu,Xichun Hu

DOI: https://doi.org/10.1158/1078-0432.ccr-21-2827

2023-01-01

Abstract:Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Supplementary Figure 6 from Enhancement of Nab-Paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer

Niranjan Awasthi,Changhua Zhang,Anna Schwarz,Stefan Hinz,Margaret A. Schwarz,Roderich E. Schwarz

DOI: https://doi.org/10.1158/1535-7163.22500697

2023-01-01

Abstract:PDF - 253K, Tumor tissue sections were stained with alpha-SMA antibody and slides were photographed under a fluorescent microscope. alpha-SMA pixel intensity was calculated and represented as bar graph. The data are expressed as the mean (plus or minus) standard deviation.

Supplementary Data 1 from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Data from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration

Supplementary Figure 8 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplementary Methods from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Methods, Figures 1-4 from Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[&lt;sup&gt;18&lt;/sup&gt;F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect

Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

Supplementary Figure 12 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary Fig.S12 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Supplementary Methods, Figures S1-14 from Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

Supplementary Figure 4 from Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Supplementary Data from A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors

Supplementary Figure 5 from Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Supplementary Figure 3 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study

Supplementary Figure 6 from Enhancement of Nab-Paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer

Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect